New AstraZeneca Study Uses STRIDE™ to Reveal Synergistic Effects of ARPi and PARP Inhibitors in Prostate Cancer
A new paper in NAR Cancers from AstraZeneca demonstrates androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.
Read the full publication here: https://academic.oup.com/
STRIDE™ was used to assess the level of double-strand DNA breaks resulting from the treatment with the androgen receptor inhibitor alone or in combination with PARP inhibitors. Our technology directly confirmed that such a combined therapy is very effective in inducing DSBs, which are one of the key drivers of cancer cells’ death.
STRIDE™ platform is helping build the kind of precision tools that can move therapies from concept to clinic.
Want to dive deeper into STRIDE?
View our YouTube channel (https://www.youtube.com/@